Simulations Plus

Fiscal 2022 revenue increased 16% year-over-year to $53.9 million
Diluted earnings per share increased 28% year-over-year to $0.60
Provides Fiscal 2023 guidance for total revenue of $59.3 million to $62.0 million (+10% to 15%)

Board of Directors announces quarterly dividend of $0.06 per share

New update expands the library of virtual populations and enhances connections between software platforms

Chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.

Management will be presenting at Baird’s 2022 Global Healthcare Conference

ILDsym will enable new software and services revenue by aiding development of therapies for the treatment of patients with ILD as a complication of systemic sclerosis

Extensive data sharing with large pharmaceutical partner will expand property prediction space and improve model performance

Several posters and oral presentations involved the use of MonolixSuite®

Tenured employees support St. Jude in finding cures and saving children

Total revenue growth of 17%; Software revenue growth of 16%; Services revenue growth of 19%;
Diluted Earnings Per Share (EPS) growth of 11%;
Board of Directors announces quarterly dividend of $0.06 per share

Record-setting attendance for the global pharmacometrics community

Simulations Plus' Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy.

Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET

DILIsym application contributes to approval of new drugs for migraine treatment

New 3D structure generation functionality and extensions to the HTPK Simulation Module among the many enhancements

FDA Renewal Ensures Access for DILIsym Evaluation of Drug Candidate Submissions

Collaboration with the US FDA and Center for Research on Complex Generics to Establish the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectables

Funded partnership with large pharmaceutical company will enhance mechanistic dissolution models for injectable formulations

Total revenue growth of 13%; Software revenue growth of 25%; Diluted Earnings Per Share (EPS) growth of 40%
Board of Directors announces quarterly dividend of $0.06 per share